Human placenta: in situ hybridization for cytomegalovirus mRNA using CMV Probe, Anti-Fluorescein Antibody and BOND Polymer Refine Detection.
Human placenta: in situ hybridization for cytomegalovirus mRNA using CMV Probe, Anti-Fluorescein Antibody and BOND Polymer Refine Detection.
BOND CMV Probe
BOND ISH probes are provided in a ready-to-use format and their use has been validated together with Leica ancillaries and BOND Polymer Refine detection for quality you can depend on. Turnaround time is rapid – around 4 hours 20 minutes using the standard BOND protocol, enabling the rapid turnaround of results vs. typical overnight protocols or outsourced testing, for improved patient care.
Background Cytomegalovirus CMV is a member of the Beta Herpes Virus family, transmitted via body fluids, and can establish primary infection, latent infection and subsequent viral reactivation.
CMV is a common opportunistic pathogen, capable of causing serious disease in immunocompromised individuals such as AIDS patients, transplant patients and in neonates.
Congenital CMV is a result of intrauterine infection and although the majority of children are asymptomatic, congenital CMV can result in sensorineural hearing loss, cognitive, motor and visual deficits and seizures.
